Erythropoietin Stimulating Agents Market is forecast to grow at a CAGR of 0.3% during 2015-2022 | Press Release Place: Publish Free Press Releases

According to a recently published report, the global Erythropoietin Stimulating Agents Market is expected to grow $7.4billion by 2022 with the CAGR of 0.3% during 2015-2022. The segmentation of global erythropoietin stimulating agents market is based on products, application, and Region. The report on global erythropoietin stimulating agents market forecast 2015-2022 (products, application and region) provides detailed overview and predictive analysis of the market.

The erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis. These EPO drugs are used for treatment of chemotherapy induced anemia. The global EPO agents market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV, and kidney failures. The cancer, HIV, kidney diseases are very chronic diseases and are responsible for large number of deaths worldwide. Over 80 % population in the world is dying from chronic diseases, 13 million are died in 2014 from cancer, more than 7.3 million are suffering from HIV, more than 4.7 million are suffering from kidney diseases and this facts is expected to rise in near future, these types of diseases cause anemia or lack of red blood cells in human body.

Full report available global erythropoietin stimulating agents market forecast 2015-2022 (products, application, and region) report at http://www.briskinsights.com/report/erythropoietin-stimulating-agents-market

An erythropoiesis stimulating agent or drug is a medicine which stimulates red blood cells protein erythropoiesis. They are used in conditions where reduced blood cells production causes anemia. The global erythropoietin stimulating agents market is driving with the rising number of anemia cases in the world. Increasing awareness of EOP therapies in the treatment of anemia also pushes the market upwards.

Scope of the report

GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET by products 2012 – 2022 ($ billion)
1.1. Epoetin-alfa
1.2. Epoetin-beta
1.3. Darbepoetin-alfa
GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET by application2012 – 2022 ($ billion)
2.1. Cancer treatments
2.2. HIV treatments
2.3. Kidney disorders
2.4. Others
GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET regional outlook 2012-2022($billion)
3.1. North America
3.2. Europe
3.3. Asia Pacific
3.4. Rest of the world
Company profiles
4.1. 3SBio
4.2. Amgen Inc.
4.3. Biocon
4.4. BioSidus
4.5. Celltrion, Inc
4.6. DR. REDDY’S LABORATORIES.
4.7. Hoffmann-La Roche
4.8. Intas Pharmaceuticals
4.9. Johnson and Johnson
4.10. LG Life Sciences Ltd.
4.11. Ranbaxy Laboratories Ltd.
4.12. Roche
4.13. RPG LIFE SCIENCES
4.14. Sandoz Hospira
4.15. Teva Pharmaceutical Industries Ltd.
Request Free Sample: http://www.briskinsights.com/sample-request/195

Related Reports:

Noble Gases Market: Industry Size, Growth, Share And Forecast To 2022
Microgrid Market: Industry Size, Growth, Share And Forecast To 2022
Feed Acidifiers Market :Industry Size, Growth, Share And Forecast To 2022
About Us:

Brisk Insights is a global Industry research firm. Our insightful analysis is focused on developed and emerging Industrys. We identify trends and forecast Industrys with a view to aid businesses identify Industry opportunities optimize strategies. Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of Industry information. Our Research and data analysis is an efficient and cost-effective way of providing robust Industry analysis and can yield highly valuable intelligence relating to consumers, competitors and Industrys.

Jennifer Smith

Office 1094

109 Vernon House

Friar Lane, Nottingham

NG16DQ, United Kingdom

Phone: +448081890034 (UK)

Email: sales@briskinsights.com

Website: http://www.briskinsights.com/